These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23097440)

  • 1. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
    Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
    J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
    Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
    J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
    Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
    Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
    Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
    Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
    Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
    Margot N; Ram R; Rhee M; Callebaut C
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
    van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
    Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
    Gatanaga H; Suzuki Y; Tsang H; Yoshimura K; Kavlick MF; Nagashima K; Gorelick RJ; Mardy S; Tang C; Summers MF; Mitsuya H
    J Biol Chem; 2002 Feb; 277(8):5952-61. PubMed ID: 11741936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1.
    Knapp DJ; Harrigan PR; Poon AF; Brumme ZL; Brockman M; Cheung PK
    J Clin Microbiol; 2011 Jan; 49(1):201-8. PubMed ID: 21084518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
    Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
    PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.